Telomerase polypeptide vaccine for treating cancer
AssigneeUltimovacs AS
InventorsGustav Gaudernack, Anne-Marie Rasmussen, Else Marit Inderberg Suso
Life of this patent
Estimating the term…
Abstract
A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.
Claims20
A method of eliciting a CD4+ and/or a CD8+ T-cell immune response in a patient with cancer or in an individual prior to any symptoms of cancer, comprising administering to the patient or the individual at least one selected from the group consisting of:
- a) a polypeptide consisting of a sequence selected from the group consisting of:
- SEQ ID NO:
- 1, or any one of SEQ ID NOS:
- 18, 24, 36 or 37;
- and
- b) a pharmaceutical composition comprising a polypeptide of part a) and a pharmaceutically acceptable adjuvant, diluent or excipient.
A method of eliciting a CD4+ and/or a CD8+ T- cell immune response in a patient with cancer or in an individual prior to any symptoms of cancer, comprising administering to the patient or the individual at least one selected from the group consisting of:
- a) a cocktail of polypeptides comprising at least first and second different polypeptides wherein the first polypeptide consists of the sequence of
- SEQ ID NO:
- 1;
- and wherein the second polypeptide comprises a sequence selected from the group consisting of:
- i) SEQ ID NOS:
- 2 to 10;
- and
- ii) a fragment of i) comprising at least eight amino acids;
- wherein the second polypeptide is less than or equal to 50 amino acids in length;
- and
- b) a pharmaceutical composition comprising a cocktail of polypeptides of part a) and a pharmaceutically acceptable adjuvant, diluent or excipient.
A method of eliciting a CD4+ and/or a CD8+ T-cell immune response in a patient with cancer or in an individual prior to any symptoms of cancer, comprising administering to the patient or the individual at least one selected from the group consisting of:
- i) a cocktail of:
- a polypeptide consisting of the sequence of SEQ ID NO:
- 1, a polypeptide comprising the sequence of SEQ ID NO:
- 7 or a fragment thereof comprising at least eight amino acids;
- and a polypeptide comprising the sequence of SEO ID NO:
- 9 or a fragment thereof comprising at least eight amino acids;
- ii) a cocktail of:
- a polypeptide comprising the sequence of SEQ ID NO:
- 1 or a fragment thereof comprising at least eight amino acids, a polypeptide consisting of the sequence of SEQ ID NO:
- 7;
- and a polypeptide comprising the sequence of SEQ ID NO:
- 9 or a fragment thereof comprising at least eight amino acids;
- and
- iii) a cocktail of:
- a polypeptide comprising the sequence of SEQ ID NO:
- 1 or a fragment thereof comprising at least eight amino acids;
- a polypeptide comprising the sequence of SEQ ID NO:
- 7 or a fragment thereof comprising at least eight amino acids;
- and a polypeptide consisting of the sequence of SEQ ID NO:
- 9,
- wherein each polypeptide is less than or equal to 50 amino acids in length.
Dependencies are inferred from the claim text.